GDAP1 and peripheral neuropathy: Treatments of peripheral neuropathies might consequently involve genetic approaches to introduce wild type MFNs and GDAP1, as shown recently in a MFN2 transgenic mouse model (Zhou et al., 2019), or pharmacological approaches to target these proteins.